GSK PLC closed 19.70% below its 52-week high of £16.79, which the company achieved on September 9th.

In a surprise, a FDA advisory panel voted that risks tied to a GSK blood cancer drug called Blenrep outweighed the benefits ...

European shares were unchanged on Friday, as losses in heavyweight healthcare shares were countered by an advance in oil and ...

(Reuters) -Bristol Myers Squibb said on Friday its blockbuster drug Reblozyl in combination with another therapy failed to ...

The panelists flagged safety concerns with Blenrep and GSK’s failure to optimize its dosing regimen for the antibody-drug ...

The pharmaceutical company said it remained confident in the benefit and risk profile of Blenrep and will continue to work ...

FDA panel rejects GSK's Blenrep combo due to severe ocular toxicity and dosing concerns in multiple myeloma trials ahead of ...

An important point about the updated guidelines is the emphasis on individualized treatment of complicated UTIs, recognizing ...

Find insight on GSK, Novartis , Sarepta Therapeutics and more in the latest Market Talks covering Health Care.

The British drugmaker was trying to revive the drug, which was pulled from U.S. markets in 2022 after failing a late-stage ...

The U.S. FDA's panel of independent advisers on Thursday recommended against GSK's blood cancer drug Blenrep, citing concerns ...

GSK Plc’s blood cancer drug failed to secure the backing of a panel of US regulatory advisers, putting its approval in doubt.